Back to top
more

Harmony Biosciences (HRMY)

(Delayed Data from NSDQ)

$34.40 USD

34.40
726,870

-0.78 (-2.22%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?

by Zacks Equity Research

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

Zacks Equity Research

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

by Zacks Equity Research

THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.

Rimmi Singhi headshot

5 High Earnings Yield Stocks to Tap Into Value Investing Gains

by Rimmi Singhi

Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.

Zacks Equity Research

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

by Zacks Equity Research

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HRMY vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sundeep Ganoria headshot

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

by Sundeep Ganoria

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 32.20% and 0.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again

by Zacks Equity Research

Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

by Sundeep Ganoria

Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.

Ekta Bagri headshot

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

by Ekta Bagri

A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.

Zacks Equity Research

Should Value Investors Buy Harmony Biosciences (HRMY) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 14.86% and 0.14%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rimmi Singhi headshot

5 High Earnings Yield Value Stocks to Buy Amid Market Volatility

by Rimmi Singhi

Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.

Zacks Equity Research

FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth

by Zacks Equity Research

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks Equity Research

Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth

by Zacks Equity Research

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Zacks Equity Research

HRMY or ONC: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. ONC: Which Stock Is the Better Value Option?

Zacks Equity Research

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

by Zacks Equity Research

AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.

Zacks Equity Research

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

by Zacks Equity Research

Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.